advanced hepatocellular carcinoma
Conditions
Interventions
Exposed group:HAIC was administered in combination with lenvatinib and tirellizumab
Non-exposed group:TACE was administered in combination with lenvatinib and tirellizumab
Sponsors
Affiliated Hospital of Guangdong Medicine University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patient age > 18 years old, no gender requirement; 2.Pathological or clinical diagnosis of unresectable hepatocellular carcinoma; 3. American Eastern Oncology Consortium (EC0C) or Activity Status (PS) score 0-1; 4.Child-Pugh grade A/B ;5.No previous systematic treatment ;6.Complete clinical data:
Exclusion criteria
Exclusion criteria: 1.Patients who are allergic to the drug being studied; 2. combined with other serious diseases such as serious heart disease and cerebrovascular embolism; 3. Exclude patients with active infectious diseases, such as active tuberculosis, syphilis, etc.; 4. pregnant or lactating women, who are in the fertile period and do not take effective contraceptive measures;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overal Survival;Progression-Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective remission rate;Disease control rate;Safety (including adverse event rate (AES), Serious Adverse Event (SAE)); | — |
Countries
China
Contacts
Public ContactLiang Qilian
Affiliated Hospital of Guangdong Medicine University
Outcome results
None listed